window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 13, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

epigenetic therapy

  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Oryzon reports strong early AML response data from iadademstat combinations at EHA 2026

    oryzon-iadademstat-aml-alice2-frida-eha-2026 Oryzon Genomics has reported updated Phase 1b data from [...]

    June 11, 2026
  • Clinical & Regulatory,Therapeutic Areas

    Rare Disease Day 2026: Cereno Scientific advances disease-modifying therapies in PAH

    As Rare Disease Day 2026 shines a spotlight on patients [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Cereno Scientific’s CS014 shows encouraging phase 1 results in idiopathic pulmonary fibrosis

    Cereno Scientific, a biotechnology company pioneering treatments for rare cardiovascular [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Oncoinvent publishes Radspherin dosimetry data in Journal of Nuclear Medicine
    Categories: Advanced Therapies, Central Nervous System, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Alamar expands Alzheimer’s proteomics partnership with 86,000 more samples
    Categories: Central Nervous System, Genomics and sequencing, Research & Development, Therapeutic Areas
  • OSF HealthCare expands RapidAI clinical AI platform to all 18 hospitals
    Categories: Biotech & Pharma Business, Central Nervous System, Clinical & Regulatory, Digital & Data, Medical devices
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top